# UC San Diego Moores Cancer Center

Source: https://onco.cc/institutions/ucsd-moores/  
OnCo record `ucsd-moores` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

San Diego's NCI comprehensive cancer centre, where the anti-GD2 antibody dinutuximab and the ROR1 antibody behind zilovertamab were developed.

## Summary

NCI-designated since 1978 and comprehensive since 2001, Moores sits at the heart of the La Jolla biomedical cluster with the Salk Institute, Sanford Burnham Prebys and Scripps. Alice Yu led the Children's Oncology Group trial that established the anti-GD2 antibody dinutuximab in high-risk neuroblastoma. Thomas Kipps's CLL laboratory generated the humanised anti-ROR1 antibody (cirmtuzumab, UC-961) that became the targeting arm of the ADC zilovertamab vedotin. The centre also runs a large precision-oncology and phase 1 programme and hosts the Sanford Stem Cell Institute.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- Also known as: Moores Comprehensive Cancer Center
- City: La Jolla, CA, US
- Type: cancer-center
- NCI designation: comprehensive
- Website: https://moorescancercenter.ucsd.edu

## Sources

- Moores Cancer Center: https://moorescancercenter.ucsd.edu
- Clinical trials: https://clinicaltrials.ucsd.edu

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [GD2 (disialoganglioside)](https://onco.cc/targets/gd2/), [ROR1](https://onco.cc/targets/ror1/)
- drugs: [Dinutuximab (ch14.18) / dinutuximab beta](https://onco.cc/drugs/dinutuximab/), [Zilovertamab vedotin](https://onco.cc/drugs/zilovertamab-vedotin/)
- companies: [Children's Oncology Group (COG)](https://onco.cc/companies/childrens-oncology-group/)
- people: [Alice L. Yu](https://onco.cc/people/alice-yu/), [Diane M. Simeone](https://onco.cc/people/diane-simeone/), [Ezra E. W. Cohen](https://onco.cc/people/ezra-cohen/), [J. Silvio Gutkind](https://onco.cc/people/j-silvio-gutkind/), [Ludmil B. Alexandrov](https://onco.cc/people/ludmil-alexandrov/), [Ramez N. Eskander](https://onco.cc/people/ramez-eskander/), [Rana McKay](https://onco.cc/people/rana-mckay/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/), [Salk Institute Cancer Center](https://onco.cc/institutions/salk-institute/), [Sanford Burnham Prebys Medical Discovery Institute](https://onco.cc/institutions/sanford-burnham-prebys/)
- key papers: [Grivennikov, Greten and Karin 2010: immunity, inflammation and cancer](https://onco.cc/key-papers/paper-grivennikov-immunity-inflammation-cancer-cell-2010/)
- trials: [I-PREDICT](https://onco.cc/trials/i-predict/), [WINTHER](https://onco.cc/trials/winther/)

---
JSON: https://onco.cc/api/v1/entities/ucsd-moores.json